Our evidence allows us to hypothesize a higher risk profile for ICAS patients with elevated plasma HMGB1, osteoprotegerin, Hs-CRP, TNF-alpha and IL-6 serum levels (Fig. 2). The gene discussed is MAP3K14; the disease is familial isolated congenital asplenia.